HIV-1 protease inhibitors with a transition-state mimic comprising a tertiary alcohol: Improved antiviral activity in cells

Journal of Medicinal Chemistry

Volumn 53, Issue 2, 2010, Pages 607-615

  Mahalingam, A K ^a   Axelsson, Linda ^a   Ekegren, Jenny K ^a   Wannberg, Johan ^a   Kihlström, Jacob ^a   Unge, Torsten ^a   Wallberg, Hans ^b   Samuelsson, Bertil ^b   Larhed, Mats ^a   Hallberg, Anders ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b MEDIVIR AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; DARUNAVIR; INDINAVIR; LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ANTIVIRAL ACTIVITY; ARTICLE; CHEMICAL REACTION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; X RAY CRYSTALLOGRAPHY;

ALCOHOLS; ANTIVIRAL AGENTS; CRYSTALLOGRAPHY, X-RAY; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; INHIBITORY CONCENTRATION 50; MOLECULAR MIMICRY; MUTATION, MISSENSE;

EID: 77249160713     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901165g     Document Type: Article

References (50)

1. Joint United Nations Programme on HIV/AIDSAIDS Epidemic Update: December 2007; UNAIDS/WHO: Geneva, 2007.
2. Brik, A.; Wong, C.-H. HIV-1 protease: mechanism and drug discovery. Org. Biomol. Chem. 2003, 1, 5-14.
3. Randolph, J. T.; DeGoey, D. A. Peptidomimetic inhibitors of HIV protease. Curr. Top. Med. Chem. 2004, 4, 1079-1095.
4. Abdel-Rahman, H. M.; Al-Karamany, G. S.; El-Koussi, N. A.; Youssef, A. F.; Kiso, Y. HIV protease inhibitors: peptidomimetic drugs and future perspectives. Curr. Med. Chem. 2002, 9, 1905-1922.
5. Rodríguez-Barrios, F.; Gago, F. HIV protease inhibition: limited recent progress and advances in understanding current pitfalls. Curr. Top. Med. Chem. 2004, 4, 991-1007.
6. Aruksakunwong,O.; Promsri, S.;Wittayanarakul, K.;Nimmanpipug, P.; Lee, V. S.; Wijitkosoom, A.; Sompornpisut, P.; Hannongbua, S. Current development onHIV-1 protease inhibitors. Curr. Comput.-Aided Drug Des. 2007, 3, 201-213.
7. Armbruster, C. HIV-1 infection: recent developments in treatment and current management strategies. Anti-Infect. Agents Med. Chem. 2008, 7, 201-214.
8. Anderson, J.; Schiffer, C.; Lee, S.-K.; Swanstrom,R. Viral protease inhibitors. Handb. Exp. Pharmacol. 2009, 189, 85-110.
9. Mastrolorenzo, A.; Rusconi, S.; Scozzafava, A.; Barbaro, G.; Supuran, C. T. Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors. Curr. Med. Chem. 2007, 14, 2734-2748.
10. Ghosh, A. K.; Sridhar, P. R.; Leshchenko, S.; Hussain, A. K.; Li, J.; Kovalevsky, A. Y.; Walters, D. E.; Wedekind, J. E.; Grum-Tokars, V.; Das, D.; Koh, Y.; Maeda, K.; Gatanaga, H.; Weber, I. T.; Mitsuya, H. Structure-Based Design of Novel HIV-1 Protease Inhibitors To Combat Drug Resistance. J. Med. Chem. 2006, 49, 5252-5261.
11. Clavel, F.; Hance, A. J. HIV drug resistance. N. Engl. J. Med. 2004, 350, 1023-1035.
12. de Mendoza, C.; Soriano,V. Resistance to HIVprotease inhibitors: mechanisms and clinical consequences. Curr. Drug Metab. 2004, 5, 321-328.
13. Menéndez-Arias, L. Targeting HIV: antiretroviral therapy and development of drug resistance. Trends Pharmacol. Sci. 2002, 23, 381-388.
14. Hertogs, K.; Bloor, S.; Kemp, S. D.; Van den Eynde, C.; Alcorn, T. M.; Pauwels, R.; Van Houtte, M.; Staszewski, S.; Miller, V.; Larder, B. A. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS (London, England) 2000, 14, 1203-1210.
15. Ekegren, J. K.; Unge, T.; Safa, M. Z.; Wallberg, H.; Samuelsson, B.; Hallberg, A. A new class of HIV-1 protease inhibitors containing a tertiary alcohol in the transition-state mimicking scaffold. J. Med. Chem. 2005, 48, 8098-8102.
16. Ekegren, J. K.; Ginman, N.; Johansson, Å.; Wallberg, H.; Larhed, M.; Samuelsson, B.; Unge, T.; Hallberg, A. Microwave accelerated synthesis of P1́-extended HIV-1 protease inhibitors encompassing a tertiary alcohol in the transition-state mimicking scaffold. J. Med. Chem. 2006, 49, 1828-1832.
17. Ekegren, J. K.; Gising, J.; Wallberg, H.; Larhed, M.; Samuelsson, B.; Hallberg, A. Variations of the P2 group in HIV-1 protease inhibitors containing a tertiary alcohol in the transition-state mimicking scaffold. Org. Biomol. Chem. 2006, 4, 3040-3043.
18. Wu, X.; Öhrngren, P.; Ekegren, J. K.; Unge, J.; Unge, T.; Wallberg, H.; Samuelsson, B.; Hallberg, A.; Larhed, M. Two-Carbon-Elongated HIV-1 Protease Inhibitors with a Tertiary-Alcohol-Containing Transition-State Mimic. J. Med. Chem. 2008, 51, 1053-1057.
19. Rich, D. H.; Bernatowicz, M. S.; Agarwal, N. S.; Kawai, M.; Salituro, F. G.; Schmidt, P. G. Inhibition of aspartic proteases by pepstatin and 3-methylstatine derivatives of pepstatin. Evidence for collected-substrate enzyme inhibition. Biochemistry 1985, 24, 3165-3173.
20. Rich, D. H. Pepstatin-derived inhibitors of aspartic proteinases. A close look at an apparent transition-state analog inhibitor. J. Med. Chem. 1985, 28, 263-273.
21. Agarwal, N. S.; Rich, D. H. Inhibition of cathepsin D by substrate analogs containing statine and by analogs of pepstatin. J. Med. Chem. 1986, 29, 2519-2524.
22. Godfrey, J. D., Jr.; Gordon, E. M.; Von Langen, D. J. Synthesis of peptide-derived amino alcohols II. Synthetic methodology for the preparation of tertiary alcohols. Tetrahedron Lett. 1987, 28, 1603-1606.
23. Kim, B. M.; Guare, J. P.; Hanifin, C. M.; Arford-Bickerstaff, D. J.; Vacca, J. P.; Ball, R. G. A convergent synthesis of novel conformationally restricted HIV-1 protease inhibitors. Tetrahedron Lett. 1994, 35, 5153-5156.
24. Balani, S. K.; Arison, B. H.; Mathai, L.; Kauffman, L. R.; Miller, R. R.; Stearns, R. A.; Chen, I. W.; Lin, J. H. Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine. Drug Metab. Dispos. 1995, 23, 266-270.
25. Lin, J. H. Role of pharmacokinetics in the discovery and development of indinavir. Adv. Drug Delivery Rev. 1999, 39, 33-49.
26. Larhed, M.; Moberg, C.; Hallberg, A. Microwave-accelerated homogeneous catalysis in organic chemistry. Acc. Chem. Res. 2002, 35, 717-727.
27. Ersmark, K.; Larhed, M.; Wannberg, J. Microwave-enhanced medicinal chemistry: A high-speed opportunity for convenient preparation of protease inhibitors. Curr. Opin. Drug Discovery Dev. 2004, 7, 417-427.
28. Kappe, C. O.; Dallinger, D. The impact of microwave synthesis on drug discovery. Nat. Rev. Drug Discovery 2006, 5, 51-63.
29. Caddick, S.; Fitzmaurice, R. Microwave enhanced synthesis. Tetrahedron 2009, 65, 3325-3355.
30. Larhed, M.; Hallberg, A. Microwave-Promoted Palladium-Catalyzed Coupling Reactions. J. Org. Chem. 1996, 61, 9582-9584.
31. Hydrazides 19 and 21 were kindly supplied by Dr. Kristina Orrling, Department of Medicinal Chemistry, Uppsala University, Sweden.
32. Robinson, B. S.; Riccardi, K. A.; Gong, Y.-F.; Guo, Q.; Stock, D. A.; Blair, W. S.; Terry, B. J.; Deminie, C. A.; Djang, F.; Colonno, R. J.; Lin, P.-F. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob. Agents Chemother. 2000, 44, 2093-2099.
33. Dorsey, B. D.; Levin, R. B.; McDaniel, S. L.; Vacca, J. P.; Guare, J. P.; Darke, P. L.; Zugay, J. A.; Emini, E. A.; Schleif, W. A.; Quintero, J. C.; Lin, J. H.; Chen, I.-W.; Holloway, M. K.; Fitzgerald, P. M. D.; Axel, M. G.; Ostovic, D.; Anderson, P. S.; Huff, J. R. L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. J. Med. Chem. 1994, 37, 3443-3451.
34. Molla, A.; Vasavanonda, S.; Kumar, G.; Sham, H. L.; Johnson, M.; Grabowski, B.; Denissen, J. F.; Kohlbrenner, W.; Plattner, J. J.; Leonard, J. M.; Norbeck, D. W.; Kempf, D. J. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology 1998, 250, 255-262.
35. Sham, H. L.; Kempf, D. J.; Molla, A.; Marsh, K. C.; Kumar, G. N.; Chen, C. M.; Kati, W.; Stewart, K.; Lal, R.; Hsu, A.; Betebenner, D.; Korneyeva, M.; Vasavanonda, S.; McDonald, E.; Saldivar, A.; Wideburg, N.; Chen, X.; Niu, P.; Park, C.; Jayanti, V.; Grabowski, B.; Granneman, G. R.; Sun, E.; Japour, A. J.; Leonard, J. M.; Plattner, J. J.; Norbeck, D. W. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother. 1998, 42, 3218-3224.
36. Ghosh Arun, K.; Dawson Zachary, L.; Mitsuya, H. Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV. Bioorg. Med. Chem. 2007, 15, 7576-7580.
37. De Meyer, S.; Azijn, H.; Surleraux, D.; Jochmans, D.; Tahri, A.; Pauwels, R.; Wigerinck, P.; de Bethune, M.-P. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob. Agents Chemother. 2005, 49, 2314-2321.
38. "N1,N6-Di[(1S)-2-methyl-1-(methylcarbamoyl) propyl]-(2R,3R,4R,-5R)-2,5-di(benzyloxy)-3, 4-dihydroxyhexanediamide.
39. Alterman, M.; Björsne, M.; Muehlman, A.; Classon, B.; Kvarnström, I.; Danielson, H.; Markgren, P.-O.; Nillroth, U.; Unge, T.; Hallberg, A.; Samuelsson, B. Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold. J. Med. Chem. 1998, 41, 3782-3792.
40. Bagossi, P.; Cheng, Y.-S. E.; Oroszlan, S.; Tozser, J. Comparison of the specificity of homo- and heterodimeric linked HIV-1 and HIV-2 proteinase dimers. Protein Eng. 1998, 11, 439-445.
41. The alpha-methyl group of Val 182 (Figure 4) has a distance of 3.8 Å to one of the ortho, 3.8 Å to the meta and 3.9 Å to the para carbon of the inhibitor benzyl group.
42. Gallivan, J. P.; Dougherty, D. A. Cation-pi interactions in structural biology. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 9459-9464.
43. The beta-methyl group of Val182 (Figure 4) has a distance of 5.1 Å to the ortho, 4.3 and 4.4 Å to the meta positions, and 3.9 Å to the para position of the inhibitor benzyl group.
44. The methyl group of mutant Thr182 (Figure 4) has a distance of 4.0 Å to the ipso, 3.8 Å to the ortho, 3.7Å to the meta, and 3.8 Å to the para carbon. The distance to the hydroxy oxygen is 5.7 Å for the ortho, 5.1 Å for the meta, and 5.0 Å for the para carbon of the inhibitor benzyl group.
45. Wang, F.; Ross, J. Atazanavir: a novel azapeptide inhibitor of HIV-1 protease. Formulary 2003, 38, 691-702.
46. Ekegren, J.;Hallberg,A.;Wallberg,H.; Samuelsson,B.;Mahalingam, K. Preparation of amino acid hydrazide derivatives and related compounds as HIV protease inhibitors. Patent WO2 006084688, 2006.
47. Moiese, J.; Arseniyadis, S.; Cossy, J. Cross-Metathesis between alpha-Methylene-gamma-butyrolactone and Olefins: A Dramatic Additive Effect. Org. Lett. 2007, 9, 1695-1698.
48. Murray, A. W.; Reid, R. G. Convenient synthesis of alphaepoxylactones (4-oxo-1,5-dioxaspiro[2.4]heptanes and -[2.5]octanes). Synthesis 1985, 35-38.
49. Shibata, I.; Yamasaki, H.; Baba, A.; Matsuda, H.ANovel Darzens type reaction promoted by tributylstannylcarbamate. J. Org. Chem. 1992, 57, 6909-6914.
50. Curran, D. P.; Ko, S.-B. Synthesis of Optically Active alpha-Hydroxy Lactones by Sharpless Asymmetric Dihydroxylations of Ketene Acetals, Enol Ethers, and Ene Lactones. J. Org. Chem. 1994, 59, 6139-6141.